Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pituitary Neoplasms × Cabergoline × Clear all

Phase

Phase 4 3 Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pituitary Neoplasms 1 Pituitary ACTH Hypersecretion 1 Adrenocortical Hyperfunction 1

Interventions

pasireotide 3 lutetium Lu 177 dotatate 1 Thyrotropin-Releasing Hormone 1 Temozolomide 1 TBR-760 1 Rosiglitazone 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 DNA Methylation 1 Cabergoline 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated

68 enrolled 25 charts

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡